Glucose monitoring leads to better outcomes25

Clinical studies show glucose monitoring are associated with better outcomes25. They also indicate that regular glucose testing is essential26, 27 to better manage overall glucose levels and reduce diabetes-related complications. With the FreeStyle Libre system, glucose monitoring is made easier.


FreeStyle Libre improves the frequency of glucose monitoring.

Two clinical studies, IMPACT and REPLACE, demonstrated that T1DM and T2DM FreeStyle Libre users safely and successfully replaced routine SMBG28.

Freestyle Libre ImprovesFreestyle Libre Improves

FreeStyle Libre users monitored their glucose almost three times as frequently compared to self-monitored blood glucose (SMBG)28.


FreeStyle Libre users also reduced routine finger pricks by over 90%, with no device-related serious adverse events29, 30.


The FreeStyle Libre system delivers important clinical benefits

The studies showed that T1DM and T2DM FreeStyle Libre users spent less time in hypoglycaemia, had fewer hypoglycaemic episodes per day, and saw no statistically significant increase in HbA1c vs SMBG 29, 30.

FreeStyle Libre SystemFreeStyle Libre System

Both T1DM and T2DM FreeStyle Libre users spent significantly less time in hypoglycemia
(<3.9 mmol/L)29, 30.


Both T1DM and T2DM FreeStyle Libre users have fewer hypoglycaemic episodes per day
(<3.9 mmol/L)29, 30.


Real-World data from Abbott's FreeStyle Libre show association between higher frequency of glucose monitoring and improved glucose control for people with diabetes31.

FreeStyle Libre Replace EvidenceFreeStyle Libre Replace Evidence

More scanning: users checked their glucose levels an average of 16 times a day31.

Test Glucose MoreTest Glucose More

Reduction in hypoglycemia

Time spent below glucose levels of 3.9 mmol/L, 3.0 mmol/L and 2.5 mmol/L decreased by 15%, 40% and 49%31.



Average glucose level decreased as scan rate increased, with estimated HbA1c decreasing from 8.0% to 6.7%31.

Clinical hba1cClinical hba1c


25 Miller KM, et al. Evidence of a strong association between frequency of self-monitoring and hemoglobin A1c levers in T1D Exchange clinic registry participants, Diabetes Care. 2013; 36(7):2009-2014.
26 Vincze G, Barner JC, Lopez D. Factors associated with adherence to self-monitoring of blood glucose among persons with diabetes. Diabetes Educ. 2004;30(1):112-125.
27 Wagner J, Malchoff C, Abbott G. Invasiveness as a barrier to self-monitoring of blood glucose in diabetes.Diabetes Technol Ther. 2005;7(4):612-619.
28 Bolinder, Jan., et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. The Lancet 388.10057 (2016): 2254-2263.
29 Data on file, Abbott Diabetes Care. An Evaluation of a Novel Glucose Sensing Technology in Type 1 Diabetes (IMPACT). [Clinical Trial Identifier: NCT02232698].
30 Data on file, Abbott Diabetes Care. An Evaluation of a Novel Glucose Sensing Technology in Type 2 Diabetes (REPLACE). [Clinical Trial Identifier: NCT02082184].
31 Dunn, T. et al. (2017). Evidence of a strong association between frequency of flash glucose monitoring and glucose control measures during real-world usage. E-poster presentation, The 10th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2017) Paris, France, 15-18 February 2017.



Images and readings are for illustration purpose only.

Refer to disclaimer here.

ADC-14425 v3.0